Effect Of A Grape Phenolic Concentrate On Plasma Cholesterol Levels In Humans | 14793
ISSN: 2165-7904

Journal of Obesity & Weight Loss Therapy
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Effect of a grape phenolic concentrate on plasma cholesterol levels in humans

2nd International Conference and Exhibition on Obesity & Weight Management

Rogerio Correa Peres, Gollucke A. P, Soares C. F, Machado O. S, Viveiros Filho V. F, Rocha S, and Ribeiro D. A

ScientificTracks Abstracts: J Obes Weight Loss Ther

DOI: 10.4172/2165-7904.S1.010

Several studies pointed atherosclerosis as the main cardiovascular disease, the leading cause of morbidity and mortality among adults in Western countries. There are a lot of studies has pointed that grape compounds as red wine or grape concentrate, rich in polyphenols, has possible antioxidant effect leading to decrease of cellular events of atherosclerosis and reduction of cardiovascular risks. This paper proposes an investigation of the effects of a 28 days diet of 70 mg daily of a grape juice concentrate rich in anthocyanidins, the G8000, on total cholesterol and its fractions, LDL, VLDL and HDL, and triglycerides, and in plasma enzymes biomarkers of muscle injury, CK, CK-MB and LDH in normal human subjects. The results showed decreased levels of plasma LDL measures, and increased levels of HDL. There are no differences for the other lipid measures. As regard the enzyme measures we observed decrease of CK_MB and increase of LDH measures, what suggest the antioxidant effect of the G8000. The results suggest that the G8000 can be considered as a tool to decrease cardiovascular diseases risks.
Rogerio Correa Peres has completed his Ph.D. at the age of 30 years from Universidade Federal de Sao Paulo-UNIFESP and he is finishing his postdoctoral studies from Universidade Federal de Sao Paulo-UNIFESP. He is the Physiology Professor of Universidade Monte Serrat-UNIMONTE and Catholic University of Santos-UNISANTOS. He has published 5 papers in reputed journals and 1 book chapter, and is serving as reviewer for more than 6 journals.